Related Experiment Video

Updated: Apr 19, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer

Min Li1,2, Ying Xue3, Yuhan Chang1,2

  • 1Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.

Nature Communications
|April 17, 2026
PubMed

Insights

Targeting ELMO2 offers a new strategy against aggressive cancers. Suppressing ELMO2 triggers cell death in mesenchymal-like cells, particularly those resistant to EGFR inhibitors, by exploiting a synthetic lethal interaction with ELMO3.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Epithelial-mesenchymal transition (EMT) promotes tumor metastasis and therapeutic resistance.
  • Targeting EMT remains a significant challenge in cancer treatment.
  • ELMO2 has emerged as a potential vulnerability in mesenchymal-like cancer cells.

Purpose of the Study:

  • To investigate the role of ELMO2 in mesenchymal-like cancer cells.
  • To identify therapeutic strategies targeting ELMO2 and its associated pathways.
  • To explore the synthetic lethal interaction between ELMO2 and ELMO3 in drug-resistant cancers.

Main Methods:

  • ELMO2 and ELMO3 gene expression analysis in cancer cell lines.
  • Investigating the effects of ELMO2 suppression on cell viability, autophagy, and FAK activity.
  • Structure-based screening to identify small-molecule inhibitors of ELMO2.
  • Assessing the efficacy of ELMO2 inhibitors in EGFR inhibitor-resistant and mesenchymal-like cancer cells.

Main Results:

  • ELMO2 suppression induces excessive autophagy and cell death via FAK inhibition in mesenchymal-like cells.
  • ELMO3 acts as a functional paralog to ELMO2, establishing a synthetic lethal interaction.
  • ZEB1 represses ELMO3 transcription, sensitizing mesenchymal-like cells to ELMO2 blockade.
  • ELMO3 downregulation is observed in EMT-associated EGFR inhibitor-resistant cells, which depend on ELMO2/FAK signaling for survival.
  • A novel small-molecule ELMO2 inhibitor, C52, effectively kills ELMO3-low and EGFR inhibitor-resistant lung cancer cells.

Conclusions:

  • An ELMO2-ELMO3 synthetic lethal interaction has been uncovered.
  • ELMO2 represents a promising therapeutic target for mesenchymal-like cancers.
  • ELMO2 inhibition is a viable strategy for treating drug-resistant non-small cell lung cancer with EMT features.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.8K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K